hla-a2 restricted glioma antigen peptides vaccine
Biologicalexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2009 (NCT01130077)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hla-a2 restricted glioma antigen peptides vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01130077 | N/A | Feb 1, 2009 | Connor's Cure, Ellie Kavalieros Fund, Translational Brain Tumor Research Fund, University of Pittsburgh |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Connor's Cure | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Ellie Kavalieros Fund | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Translational Brain Tumor Research Fund | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2009 |
4 organizations
Page 1 / 1